[go: up one dir, main page]

DK4268843T3 - Forbedrede IL-6-antistoffer - Google Patents

Forbedrede IL-6-antistoffer

Info

Publication number
DK4268843T3
DK4268843T3 DK23189385.0T DK23189385T DK4268843T3 DK 4268843 T3 DK4268843 T3 DK 4268843T3 DK 23189385 T DK23189385 T DK 23189385T DK 4268843 T3 DK4268843 T3 DK 4268843T3
Authority
DK
Denmark
Prior art keywords
antibodies
improved
Prior art date
Application number
DK23189385.0T
Other languages
English (en)
Inventor
Michael March Schmidt
Alison Tisdale
Eric Steven Furfine
Grigorios Zarbis-Papastoitsis
Original Assignee
F Hoffmann La Roche Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche Ltd filed Critical F Hoffmann La Roche Ltd
Application granted granted Critical
Publication of DK4268843T3 publication Critical patent/DK4268843T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK23189385.0T 2014-11-07 2015-11-06 Forbedrede IL-6-antistoffer DK4268843T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462077105P 2014-11-07 2014-11-07
US201462087448P 2014-12-04 2014-12-04
US201562247705P 2015-10-28 2015-10-28
EP19189890.7A EP3632931A1 (en) 2014-11-07 2015-11-06 Improved il-6 antibodies

Publications (1)

Publication Number Publication Date
DK4268843T3 true DK4268843T3 (da) 2025-11-10

Family

ID=54602042

Family Applications (2)

Application Number Title Priority Date Filing Date
DK23189385.0T DK4268843T3 (da) 2014-11-07 2015-11-06 Forbedrede IL-6-antistoffer
DK15797538T DK3215530T3 (da) 2014-11-07 2015-11-06 Forbedrede il-6 antistoffer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15797538T DK3215530T3 (da) 2014-11-07 2015-11-06 Forbedrede il-6 antistoffer

Country Status (32)

Country Link
US (3) US11142571B2 (da)
EP (3) EP3632931A1 (da)
JP (1) JP6594438B2 (da)
KR (2) KR102636726B1 (da)
CN (1) CN107249631B (da)
AU (1) AU2015342882B2 (da)
CA (1) CA2965689C (da)
CL (1) CL2017001135A1 (da)
CO (1) CO2017005404A2 (da)
CR (1) CR20170231A (da)
DK (2) DK4268843T3 (da)
EA (1) EA035199B1 (da)
ES (1) ES2756275T3 (da)
FI (1) FI4268843T3 (da)
HR (1) HRP20191945T1 (da)
HU (1) HUE046181T2 (da)
IL (1) IL251858B (da)
LT (1) LT4268843T (da)
MA (1) MA51554A (da)
MX (2) MX385206B (da)
MY (1) MY185114A (da)
PE (1) PE20171107A1 (da)
PH (1) PH12017500809B1 (da)
PL (1) PL3215530T3 (da)
PT (2) PT3215530T (da)
RS (1) RS59805B1 (da)
SA (1) SA517381458B1 (da)
SG (2) SG10202103420PA (da)
SI (1) SI3215530T1 (da)
UA (1) UA122673C2 (da)
WO (1) WO2016073890A1 (da)
ZA (1) ZA201702985B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3353203A2 (en) 2015-09-23 2018-08-01 H. Hoffnabb-La Roche Ag Optimized variants of anti-vegf antibodies
AR107708A1 (es) * 2016-02-23 2018-05-23 Eleven Biotherapeutics Inc Formulaciones de antagonista de il-6 y sus usos
MX2019007144A (es) * 2016-12-19 2019-10-07 Glenmark Pharmaceuticals Sa Nuevos agonistas de tnfr y sus usos.
JP7216006B2 (ja) 2017-03-22 2023-01-31 ジェネンテック， インコーポレイテッド ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
UA129242C2 (uk) 2017-03-22 2025-02-26 Дженентек, Інк. Оптимізована композиція антитіла для лікування захворювань очей
CN109867723B (zh) * 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途
PE20230252A1 (es) 2020-03-13 2023-02-07 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos de estos
BR112022018847A2 (pt) 2020-03-24 2022-11-22 Genentech Inc Anticorpos, ácido nucleico, célula hospedeira, conjugados, composição farmacêutica, dispositivo de entrega de ação prolongada para entrega ocular, método para tratar um distúrbio e uso do anticorpo
EP4228706A1 (en) 2020-10-15 2023-08-23 Genentech, Inc. Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics
CN116554298A (zh) * 2022-02-25 2023-08-08 南京工业大学 一种强化细菌卷曲菌毛提高人表皮生长因子分泌生产效率的方法
CN115343483B (zh) * 2022-08-12 2024-11-26 苏州邦器生物技术有限公司 一种自身免疫性糖尿病检测用试剂盒及其制备方法
CN120112551A (zh) * 2022-10-24 2025-06-06 豪夫迈·罗氏有限公司 预测对il-6拮抗剂的反应

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4548990A (en) 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
WO1992015677A1 (en) 1991-03-01 1992-09-17 Protein Engineering Corporation Process for the development of binding mini-proteins
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Technology Ltd., Melbourn Methoden zur Herstellung humanisierter Antikörper
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
FR2734739B1 (fr) 1995-06-01 1997-07-11 Gec Alsthom Stein Ind Dispositif de surveillance d'un broyeur a boulets
TW311927B (da) 1995-07-11 1997-08-01 Minnesota Mining & Mfg
EP0795743A3 (en) 1996-03-15 1998-02-25 Japan Tobacco Inc. Method and apparatus for infra-red moisture measurement
US5839430A (en) 1996-04-26 1998-11-24 Cama; Joseph Combination inhaler and peak flow rate meter
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998050431A2 (en) 1997-05-02 1998-11-12 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6358058B1 (en) 1998-01-30 2002-03-19 1263152 Ontario Inc. Aerosol dispensing inhaler training device
EP1137941B2 (en) 1998-12-10 2013-09-11 Bristol-Myers Squibb Company Protein scaffolds for antibody mimics and other binding proteins
CA2381770C (en) 1999-08-24 2007-08-07 Medarex, Inc. Human ctla-4 antibodies and their uses
EP1354034B8 (en) 2000-11-30 2008-06-18 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
ATE472609T1 (de) 2001-04-26 2010-07-15 Amgen Mountain View Inc Kombinatorische bibliotheken von monomerdomänen
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
AU2003234439A1 (en) 2002-05-07 2003-11-11 Control Delivery Systems, Inc. Processes for forming a drug delivery device
JP2006516957A (ja) * 2002-11-15 2006-07-13 セントカー・インコーポレーテツド Ｉｌ−６アンタゴニストの抗血管形成用途
BRPI0417270A (pt) 2003-12-23 2007-03-27 Rinat Neuroscience Corp anticorpos agonistas antitrkc e métodos para utilização dos mesmos
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
MX2007002856A (es) 2004-09-02 2007-09-25 Genentech Inc Metodos para el uso de ligandos receptores de muerte y anticuerpos c20.
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
CA2635615A1 (en) 2005-12-30 2007-07-12 Merck Patent Gesellschaft Mit Beschraenkter Haftung Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
JP2009529339A (ja) 2006-03-13 2009-08-20 アブリンクス エン．ヴェー． Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド
EP2021463B1 (en) 2006-05-19 2016-11-23 Alder Biopharmaceuticals, Inc. Culture method for obtaining a clonal population of antigen-specific b cells
ES2721753T3 (es) * 2007-05-21 2019-08-05 Alderbio Holdings Llc Anticuerpos contra IL-6 y usos de los mismos
MX2010002815A (es) 2007-09-14 2010-07-30 Sanofi Pasteur Biologics Co Composiciones farmaceuticas que contienen toxoides a y b de clostridium difficile.
US8043620B2 (en) 2007-11-21 2011-10-25 Amgen Inc. Wise binding agents and epitopes
US20100187601A1 (en) 2007-12-12 2010-07-29 Fujio Masuoka Semiconductor device
MX2010007728A (es) 2008-01-15 2010-12-21 Abbott Gmbh & Co Kg Composiciones proteinicas en polvo y metodos para elaborar las mismas.
HRP20150799T1 (hr) 2008-08-05 2015-09-11 Novartis Ag Sastavi i postupci za protutijela protiv komplementnog proteina c5
WO2010029748A1 (ja) 2008-09-12 2010-03-18 有限会社眞友商会 噴水装置
WO2010039750A2 (en) 2008-10-01 2010-04-08 Monsanto Technology Llc Transgenic plants with enhanced agronomic traits
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
BRPI0921319A2 (pt) 2008-11-26 2018-10-16 Glaxo Group Ltd composição, método para dispensação de uma composição, e para tratar, prevenir ou diagnosticar uma condição ocular, e, processo para produzir uma composição farmacêutica
BRPI1007005A2 (pt) 2009-01-29 2016-03-22 Medimmune Llc anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2593142B8 (en) 2010-07-12 2018-12-26 Pfizer Healthcare Ireland Multifunctional antibody conjugates
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
HK1214499A1 (zh) 2012-10-25 2016-07-29 Medimmune, Llc 穩定的低粘度抗體配製品
AU2013342163B2 (en) 2012-11-08 2018-08-16 F. Hoffmann-La Roche Ltd IL-6 antagonists and uses thereof
AU2014286996A1 (en) 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention

Also Published As

Publication number Publication date
JP2017535285A (ja) 2017-11-30
SG10202103420PA (en) 2021-05-28
PL3215530T3 (pl) 2020-05-18
PH12017500809B1 (en) 2023-09-20
EP3215530B1 (en) 2019-08-21
ES2756275T3 (es) 2020-04-27
EA035199B1 (ru) 2020-05-14
LT4268843T (lt) 2025-11-25
EP4268843A2 (en) 2023-11-01
UA122673C2 (uk) 2020-12-28
ES2756275T9 (es) 2020-10-29
WO2016073890A1 (en) 2016-05-12
AU2015342882B2 (en) 2021-05-20
MA51554A (fr) 2020-11-18
CL2017001135A1 (es) 2017-12-15
AU2015342882A1 (en) 2017-05-18
KR20170077196A (ko) 2017-07-05
US20190194312A1 (en) 2019-06-27
SA517381458B1 (ar) 2020-07-09
HRP20191945T1 (hr) 2020-01-24
FI4268843T3 (fi) 2025-11-14
US11142571B2 (en) 2021-10-12
SI3215530T1 (sl) 2020-02-28
JP6594438B2 (ja) 2019-10-23
EP3632931A1 (en) 2020-04-08
BR112017008672A2 (pt) 2018-03-20
EP4268843A3 (en) 2023-12-27
MX385206B (es) 2025-03-14
ZA201702985B (en) 2019-10-30
CR20170231A (es) 2017-09-25
EP3215530B9 (en) 2020-09-09
KR102636726B1 (ko) 2024-02-13
MY185114A (en) 2021-04-30
RS59805B1 (sr) 2020-02-28
US20220169719A1 (en) 2022-06-02
DK3215530T3 (da) 2019-11-25
KR20240023450A (ko) 2024-02-21
HUE046181T2 (hu) 2020-02-28
KR102770849B1 (ko) 2025-02-20
SG11201703574VA (en) 2017-05-30
IL251858B (en) 2022-09-01
MX2021008663A (es) 2021-08-19
PE20171107A1 (es) 2017-08-07
EA201791005A1 (ru) 2017-09-29
NZ731090A (en) 2024-03-22
CO2017005404A2 (es) 2017-10-31
EP3215530A1 (en) 2017-09-13
PT3215530T (pt) 2019-11-21
CA2965689C (en) 2022-03-22
CA2965689A1 (en) 2016-05-12
HK1244008A1 (en) 2018-07-27
US20250059270A1 (en) 2025-02-20
PT4268843T (pt) 2025-10-31
EP4268843B1 (en) 2025-09-03
CN107249631B (zh) 2021-11-23
IL251858A0 (en) 2017-06-29
PH12017500809A1 (en) 2017-10-02
CN107249631A (zh) 2017-10-13
MX2017005992A (es) 2017-09-15

Similar Documents

Publication Publication Date Title
NL301117I1 (nl) trastuzumab deruxtecan
DK3344654T3 (da) Anti-lag-3-antistoffer
SI3354729T1 (sl) Protitelesa anti-garp
DK3126395T3 (da) Multispecifikke antistoffer
PL3556777T3 (pl) Konstrukty przeciwciał wieloswoistych
DK3160994T3 (da) Multispecifikke antigenbindende proteiner
HUE060878T2 (hu) Anti-transztiretin antitestek
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
DK3250593T3 (da) Anti-transthyretin-antistoffer
CL2016001742A1 (es) Anticuerpos anti-baff novedosos
IL256099A (en) Antibody
IL291164A (en) Anti-nme antibody
DK4268843T3 (da) Forbedrede IL-6-antistoffer
LT3092003T (lt) Naujas anti-netrino-1 antikūnas
DK3484921T3 (da) Anti-IL-22R antistoffer
DK3452515T3 (da) Her-2-bindende antistoffer
LT3178931T (lt) Anti-orai1 antikūnas
LT3126391T (lt) Hpa-1a antikūnai
LT3628731T (lt) Naujas antipresepsino antikūnas
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3